Document is current
Any future updates will be listed below
-
Authors
Auger, Anick
Faidi, Rania
Rickman, Alexis D.
Martinez, Carolina Pena
Fajfer, Austin
Carling, Jeremy
Hilyard, Addison
Ali, Mubashshir
Ono, Ryosuke
Cleveland, Connor
Seliniotakis, Ria
Truong, Nhi
Chefson, Amandine
Raymond, Marianne
Germain, Marie-Anne
Crackower, Michael A.
Heckmann, Bradlee L.
-
Funding
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS124783)
Ventus Therapeutics (N/A)
- License Information
-
More Information
Article History
Received: 27 November 2024
Accepted: 21 April 2025
First Online: 6 May 2025
Competing interests
: A.A., R.F., R.S., M.-A.G. and A.C. declare they are employees of Ventus Therapeutics, Inc., based in Montreal, Canada, and M.A.C. is an employee of Ventus Therapeutics U.S., Inc., based in Waltham, Massachusetts, USA. M.R. was a former employee at Ventus Therapeutics, Inc., based in Montreal, Canada. Ventus Therapeutics Inc. is a subsidiary of Ventus Therapeutics U.S., Inc., collectively referred to herein as “Ventus”. B.L.H. consults for Ventus and is the co-founder and CSO of Asha Therapeutics.
: No human participants were used in the present study. All animal studies were approved by the University of South Florida Institutional Animal Care and Use Committee prior to study initiation.
